Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Efficacy and safety of Sorafenib as monotherapy to FLT3-ITD positive acute myeloid leukemia].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 14 Dec 2016

Jia J S, Zhu H H, Fu H X, Gong L Z, Kong J, Huang X J, Jiang H

Abstract excerpt

Objective: To explore the efficacy and safety of Sorafenib as monotherapy to FLT3 positive acute myeloid leukemia (AML). Methods: From April 2014 to December 2015, fourteen AML patients with FLT3 positive, 7 males and 7 females with a median age of 42 (range: 14-81) years old, were enrolled in this study. Of the 14 cases, 4 were de novo cases, 9 refractory cases and 1 relapsed case, including 78.6% patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Remission Induction

Share to Sorafenib

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 28088962
DOI: 10.3760/cma.j.issn.0253-2727.2016.12.002
PMCID: PMC7348496

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Efficacy and safety of Sorafenib as monotherapy to FLT3-ITD positive acute myeloid leukemia].PMID 28088962Read ↗

[Sorafenib in combination with chemotherapy as first-line therapy for FLT3-ITD positive acute myeloid leukemia].Semantic proximity Read ↗

[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].Semantic proximity Read ↗

[Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].Semantic proximity Read ↗

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].Semantic proximity Read ↗

Characteristics and Outcome of FLT3-ITD-Positive Acute Myeloid Leukemia.Semantic proximity Read ↗

Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.Semantic proximity Read ↗

[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].Semantic proximity Read ↗

Prognosis and outcome of patients with acute myeloid leukemia based on FLT3‑ITD mutation with or without additional abnormal cytogeneticsSemantic proximity Read ↗

[Clinical Characteristics and Prognosis of Acute Myeloid Leukemia with FLT3-ITD Mutation].Semantic proximity Read ↗

[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].Semantic proximity Read ↗

Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.